Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) – Analysts at Capital One Financial lowered their Q4 2022 earnings estimates for Ironwood Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 25th. Capital One Financial analyst T. Chiang now expects that the biotechnology company will earn $0.25 per share for the quarter, down from their previous forecast of $0.29. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $1.00 per share.
Get Ironwood Pharmaceuticals alerts:Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. The company had revenue of $108.64 million for the quarter, compared to the consensus estimate of $111.51 million. Ironwood Pharmaceuticals had a return on equity of 30.24% and a net margin of 39.85%.
Separately, StockNews.com cut shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, December 17th.Ironwood Pharmaceuticals Stock Up 1.6 %
NASDAQ IRWD opened at $11.49 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 25.78 and a current ratio of 25.78. The firm has a 50-day simple moving average of $11.88 and a 200 day simple moving average of $11.37. Ironwood Pharmaceuticals has a twelve month low of $9.73 and a twelve month high of $12.95. The stock has a market cap of $1.76 billion, a PE ratio of 12.09 and a beta of 0.96.
Institutional Trading of Ironwood Pharmaceuticals
Several hedge funds have recently modified their holdings of the company. Natixis Advisors L.P. acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth approximately $340,000. Ritholtz Wealth Management increased its holdings in shares of Ironwood Pharmaceuticals by 46.8% in the fourth quarter. Ritholtz Wealth Management now owns 71,164 shares of the biotechnology company's stock valued at $882,000 after purchasing an additional 22,692 shares in the last quarter. Maryland State Retirement & Pension System acquired a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at approximately $683,000. Ronald Blue Trust Inc. increased its holdings in shares of Ironwood Pharmaceuticals by 18,584.6% in the fourth quarter. Ronald Blue Trust Inc. now owns 4,858 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 4,832 shares in the last quarter. Finally, MQS Management LLC increased its holdings in shares of Ironwood Pharmaceuticals by 77.5% in the third quarter. MQS Management LLC now owns 20,729 shares of the biotechnology company's stock valued at $215,000 after purchasing an additional 9,048 shares in the last quarter.
Insiders Place Their Bets
In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 110,962 shares of the firm's stock in a transaction dated Thursday, January 5th. The shares were sold at an average price of $12.07, for a total transaction of $1,339,311.34. Following the completion of the transaction, the chief executive officer now owns 712,440 shares in the company, valued at $8,599,150.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 13.10% of the company's stock.
Ironwood Pharmaceuticals Company Profile
(Get Rating)
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.
Featured Stories
- Get a free copy of the StockNews.com research report on Ironwood Pharmaceuticals (IRWD)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.